Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. N-(3-(5-(2-cyclopropylpyrimidin-5-yl)-1h-pyrrolo(2,3-b)pyridine-3-carbonyl)-2,4-difluorophenyl)-3-fluoropyrrolidine-1-sulfonamide
2. Plx8394
1. Plx8394
2. 1393466-87-9
3. Plx-8394
4. J2l7z273sg
5. Plx 8394
6. (3r)-n-[3-[5-(2-cyclopropylpyrimidin-5-yl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluorophenyl]-3-fluoropyrrolidine-1-sulfonamide
7. 1-pyrrolidinesulfonamide, N-(3-((5-(2-cyclopropyl-5-pyrimidinyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-3-fluoro-, (3r)-
8. Unii-j2l7z273sg
9. Gtpl9131
10. Chembl4303729
11. Schembl15666953
12. Plx 8394 [who-dd]
13. Bdbm317826
14. Bcp19619
15. Ex-a1461
16. Plx 8394;plx8394
17. Nsc797932
18. Nsc801007
19. S7965
20. Zinc144705377
21. Cs-5123
22. Nsc-797932
23. Nsc-801007
24. Us9624213, Compound P-0338
25. Ncgc00483921-01
26. Ac-36850
27. Bp168493
28. Bs-15485
29. Hy-18972
30. A16840
31. D83660
32. A900333
33. Q27088419
| Molecular Weight | 542.5 g/mol |
|---|---|
| Molecular Formula | C25H21F3N6O3S |
| XLogP3 | 2.8 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 11 |
| Rotatable Bond Count | 7 |
| Exact Mass | 542.13479421 g/mol |
| Monoisotopic Mass | 542.13479421 g/mol |
| Topological Polar Surface Area | 129 Ų |
| Heavy Atom Count | 38 |
| Formal Charge | 0 |
| Complexity | 976 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Plixorafenib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Plixorafenib, including repackagers and relabelers. The FDA regulates Plixorafenib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Plixorafenib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Plixorafenib supplier is an individual or a company that provides Plixorafenib active pharmaceutical ingredient (API) or Plixorafenib finished formulations upon request. The Plixorafenib suppliers may include Plixorafenib API manufacturers, exporters, distributors and traders.
Plixorafenib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Plixorafenib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Plixorafenib GMP manufacturer or Plixorafenib GMP API supplier for your needs.
A Plixorafenib CoA (Certificate of Analysis) is a formal document that attests to Plixorafenib's compliance with Plixorafenib specifications and serves as a tool for batch-level quality control.
Plixorafenib CoA mostly includes findings from lab analyses of a specific batch. For each Plixorafenib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Plixorafenib may be tested according to a variety of international standards, such as European Pharmacopoeia (Plixorafenib EP), Plixorafenib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Plixorafenib USP).
LOOKING FOR A SUPPLIER?
